Cargando…
Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database
BACKGROUND: Anti-HER2 therapy has evolved in the last years and an important role in this transformation was that of monoclonal antibodies and tyrosine kinase inhibitors. Considering their extended use in clinical practice, some toxicity problems have been highlighted around these drugs. OBJECTIVE:...
Autores principales: | Barbieri, Maria Antonietta, Sorbara, Emanuela Elisa, Cicala, Giuseppe, Santoro, Vincenza, Cutroneo, Paola Maria, Franchina, Tindara, Spina, Edoardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844323/ https://www.ncbi.nlm.nih.gov/pubmed/34528216 http://dx.doi.org/10.1007/s40801-021-00278-z |
Ejemplares similares
-
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022) -
Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022) -
Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database
por: Russo, Giulia, et al.
Publicado: (2023) -
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023) -
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)